Elitek Related Published Studies
Well-designed clinical trials related to Elitek (Rasburicase)
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. [2001.05.15]
Other research related to Elitek (Rasburicase)
[Rasburicase therapy may cause hydrogen peroxide shock] [2008.08.24]
Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. [2008.04]
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase. [2008.04]
SFCE (Societe Francaise de Lutte contre les Cancers et Leucemies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey. [2008.04]
Rasburicase in the prevention and treatment of tumour lysis syndrome. [2008.02]
Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease. [2008]
[Efficacy of rasburicase therapy in obstructive renal failure secondary to urolithiasis: a novel therapeutic option] [2008]
Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. [2007.10]
Catalase deficiency may complicate urate oxidase (rasburicase) therapy. [2007.09]
Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study. [2007.05]
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. [2007.03.02]
Clarifying the role of rasburicase in tumor lysis syndrome. [2007.01]
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. [2007]
Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. [2006.09]
Rasburicase for the management of tumor lysis syndrome in neonates. [2006.07]
Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. [2006.06]
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. [2006.06]
Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. [2006.06]
Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea. [2006.04]
[Analysis and protocolization of rasburicase use in patients with hematologic neoplasms] [2006.03]
Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. [2006.02]
Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapy. [2006.01]
Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. [2006]
Spotlight on rasburicase in anticancer therapy-induced hyperuricemia. [2006]
Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. [2006]
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. [2005.12]
Hemolysis and methemoglobinemia secondary to rasburicase administration. [2005.11]
A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. [2005.04]
Managing malignancy-associated hyperuricemia with rasburicase. [2005.03]
Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. [2005.01]
Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. [2005]
Rasburicase therapy in acute hyperuricemia and renal dysfunction. [2005]
Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. [2005]
Management of hyperuricemia with rasburicase review. [2004.10]
Stabilization of rasburicase and physico-chemical characterization of the resulting injectable formulation. [2004.09]
[Rasburicase (Fasturtec)] [2004.09]
Use of single-dose rasburicase in an obese female. [2004.09]
Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis. [2004.08]
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. [2003.12.01]
Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. [2003.11.01]
Treatment of impending tumor lysis with single-dose rasburicase. [2003.11]
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. [2003.09.01]
Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. [2003.08]
Rasburicase for the treatment and prevention of hyperuricemia. [2003.07]
Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. [2003.04]
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. [2003.03]
Rasburicase: a potent uricolytic agent. [2002.04]
Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome. [2002.01]
Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. [2001.10]
Rasburicase. [2001]
Other possibly related research studies
Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. [2005.01]
Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica. [2005]
Hyperuricemic syndromes in cancer patients. [2005]
Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. [2005]
Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. [2003.03]
Prevention and treatment of hyperuricemia in hematological malignancies. [2002.12]
Challenges in the management of Burkitt's lymphoma. [2002.12]
Gateways to clinical trials. [2005.09]
[Tumor lysis syndrome: risk factors and treatment] [2005.01]
Gateways to clinical trials. [2005.03]
Current management of gout in patients unresponsive or allergic to allopurinol. [2004.11]
Gateways to clinical trials. [2004.05]
Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. [2004.04.15]
[Gout] [2004.02]
Gateways to clinical trials. [2003.09]
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002. [2003.12]
Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden. [2003.05]
Acute tumor lysis syndrome in solid tumors--a case report and review of the literature. [2003.03]
Gateways to Clinical Trials. June 2002. [2002.06]
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. [2001.10]
European experience in the treatment of hyperuricemia. [2001.10]
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. [2001.02.01]
Gateways to clinical trials. [2006.09]
Newer therapeutic approaches: gout. [2006.02]
Gateways to clinical trials. [2006.07]
The management of tumor lysis syndrome. [2006.08]
Management of tumor lysis syndrome in adults. [2007.02]
Emerging therapies in the long-term management of hyperuricaemia and gout. [2007.04]
Acute renal failure from xanthine nephropathy during management of acute leukemia. [2007.01]
[The pathophysiology, clinical signs and therapy of urate nephropathy] [2007.04.22]
Gateways to clinical trials. [2007.09]
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. [2008.06.01]
|
